GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Research & Development

Syntara (ASX:SNT) Research & Development : A$0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Syntara Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Syntara's Research & Development for the six months ended in Dec. 2023 was A$0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.


Syntara Research & Development Historical Data

The historical data trend for Syntara's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syntara Research & Development Chart

Syntara Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Syntara Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Syntara Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Syntara  (ASX:SNT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Syntara Research & Development Related Terms

Thank you for viewing the detailed overview of Syntara's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.


Syntara Business Description

Traded in Other Exchanges
Address
20 Rodborough Road, Unit 2, Frenchs Forest, Sydney, NSW, AUS, 2086
Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring, and neuroinflammation.

Syntara Headlines

From GuruFocus

Q2 2022 Senstar Technologies Ltd Earnings Call Transcript

By GuruFocus Research 02-09-2024

Senstar Technologies Corporation

By PRNewswire 08-26-2024

Magal Security Systems Ltd. - Special Call Transcript

By GuruFocus Research 02-09-2024

Q2 2024 Senstar Technologies Ltd Earnings Call Transcript

By GuruFocus Research 08-27-2024

Q2 2023 Senstar Technologies Ltd Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q3 2022 Senstar Technologies Ltd Earnings Call Transcript

By GuruFocus Research 02-09-2024

Q4 2023 Senstar Technologies Ltd Earnings Call Transcript

By GuruFocus Research 04-20-2024